Profile data is unavailable for this security.
About the company
Pharma Foods International Co., Ltd. is a Japan-based company mainly engaged in mail order business and functional materials business. The Company operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The Company is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.
- Revenue in JPY (TTM)63.21bn
- Net income in JPY3.87bn
- Incorporated1997
- Employees670.00
- LocationPharma Foods International Co Ltd1-49, Goryo Ohara, Nishikyo-KuKYOTO-SHI 615-8245JapanJPN
- Phone+81 753948600
- Fax+81 753940099
- Websitehttps://www.pharmafoods.co.jp/
Mergers & acquisitions
Acquired company | 2929:TYO since announced | Transaction value |
---|---|---|
Daicel Corp-Healthcare Mail Order Business | -31.38% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharma Foods International Co., Ltd. | 63.21bn | 3.87bn | 29.52bn | 670.00 | 7.51 | 2.85 | 6.57 | 0.4669 | 135.20 | 135.20 | 2,207.45 | 356.76 | 1.75 | 2.10 | 12.31 | 94,343,280.00 | 10.69 | 8.40 | 35.14 | 19.20 | 79.54 | 81.34 | 6.12 | 3.85 | 0.8573 | 93.61 | 0.6565 | 28.26 | 13.94 | 53.90 | 923.80 | 57.92 | 51.63 | -- |
TOT Biopharm International Co Ltd | 17.34bn | -838.58m | 30.02bn | 551.00 | -- | 1.97 | 277.44 | 1.73 | -0.056 | -0.056 | 1.16 | 0.9551 | 0.5808 | 1.87 | 8.03 | 1,522,748.00 | -2.81 | -20.01 | -3.72 | -25.21 | 73.53 | 74.74 | -4.84 | -68.53 | 1.48 | -4.60 | 0.3348 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
CStone Pharmaceuticals | 10.30bn | -8.16bn | 30.25bn | 230.00 | -- | 2.98 | -- | 2.94 | -0.3129 | -0.3129 | 0.3947 | 0.3824 | 0.2811 | 2.44 | 3.72 | 2,167,590.00 | -22.25 | -54.76 | -48.85 | -81.68 | 65.60 | -- | -79.17 | -301.62 | 1.44 | -- | 0.4431 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
Frontage Holdings Corp | 41.95bn | 1.74bn | 30.71bn | 1.76k | 17.87 | 0.5549 | 4.11 | 0.732 | 0.0409 | 0.0409 | 0.9808 | 1.32 | 0.463 | 60.63 | 5.32 | 1,154,072.00 | 1.91 | 4.46 | 2.33 | 5.28 | 30.17 | 34.00 | 4.13 | 9.92 | 1.39 | 4.09 | 0.296 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
Dimerix Ltd | 19.51m | -1.17bn | 31.09bn | 0.00 | -- | 130.32 | -- | 1,593.41 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
Race Oncology Ltd | 95.33m | -1.20bn | 31.99bn | -- | -- | 13.96 | -- | 335.57 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
Wuhan YZY Biopharma Co Ltd | 0.00 | -4.26bn | 32.37bn | 123.00 | -- | 11.42 | -- | -- | -1.11 | -1.11 | 0.00 | 0.7078 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 1.41 | -100.12 | 0.4138 | -- | -- | -- | -1.50 | -- | -- | -- |
Hua Medicine | 1.70bn | -4.69bn | 32.94bn | 177.00 | -- | 13.62 | -- | 19.36 | -0.2323 | -0.2323 | 0.0843 | 0.1109 | 0.0538 | 1.69 | 13.03 | 465,208.00 | -14.84 | -25.61 | -17.56 | -28.81 | 48.78 | -- | -275.73 | -1,654.70 | 6.06 | -- | 0.6238 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 May 2024 | 842.38k | 2.90% |
Nomura Asset Management Co., Ltd.as of 31 May 2024 | 823.80k | 2.83% |
Nikko Asset Management Co., Ltd.as of 07 Jun 2024 | 382.40k | 1.32% |
Daiwa Asset Management Co. Ltd.as of 31 May 2024 | 361.30k | 1.24% |
Norges Bank Investment Managementas of 31 Dec 2023 | 359.90k | 1.24% |
Dimensional Fund Advisors LPas of 06 Jun 2024 | 246.20k | 0.85% |
SSgA Funds Management, Inc.as of 06 Jun 2024 | 165.70k | 0.57% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Jun 2024 | 160.60k | 0.55% |
BlackRock Fund Advisorsas of 06 Jun 2024 | 82.50k | 0.28% |
BlackRock Japan Co. Ltd.as of 06 Jun 2024 | 65.90k | 0.23% |